The deadline to submit letters of intent for the Cancer Research Institute’s Technology Impact Award is only one month away (Thursday, November 15). CRI’s newest program is designed to encourage collaboration between technology developers and clinical cancer immunologists in addressing the gap between technology development and clinical application of cancer immunotherapies.

The award will provide funding of $200,000 over two years.

The ultimate aim of this program is to advance technologies that can speed up the entire field’s efforts in addressing one of the most defining challenges of our time – developing immunotherapies that are effective for all cancer patients. The most competitive applicants will address areas where technological innovation stands to benefit the field and cancer patients most, and that will ultimately lead to effective next generation personalized cancer immunotherapies. Applicants must hold a faculty appointment as a tenure-track assistant professor (or higher rank) at the time of award activation. Successful candidates will be eligible for follow-on funding to enable established proof-of-concept technology to be developed into a methodology that improves cancer immunotherapy research worldwide. Selected applicants will be invited to submit a full research proposal, due Friday, March 15, 2019. Submit your letter of intent.